Petros Pharmaceuticals Stock Performance
| PTPI Stock | USD 0.29 0.02 7.41% |
The company holds a Beta of -0.54, which implies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Petros Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, Petros Pharmaceuticals is likely to outperform the market. At this point, Petros Pharmaceuticals has a negative expected return of -0.16%. Please make sure to check Petros Pharmaceuticals' value at risk, daily balance of power, as well as the relationship between the Daily Balance Of Power and period momentum indicator , to decide if Petros Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Petros Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest unfluctuating performance, the Stock's basic indicators remain strong and the recent confusion on Wall Street may also be a sign of long-lasting gains for the firm traders. ...more
Last Split Factor 1:10 | Last Split Date 2022-12-01 |
1 | Petros Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference | 09/03/2024 |
2 | Petros Pharmaceuticals sets date for 2024 annual meeting - Investing.com | 09/19/2024 |
3 | Insider Trading | 09/20/2024 |
4 | Board Reshuffle at Petros Pharmaceuticals Following Resignations - TipRanks | 10/04/2024 |
5 | Acquisition by John Shulman of 1661807 shares of Petros Pharmaceuticals at 1.715 subject to Rule 16b-3 | 11/08/2024 |
6 | Acquisition by Gesek Andrew of tradable shares of Petros Pharmaceuticals at 3.99 subject to Rule 16b-3 | 11/20/2024 |
| Begin Period Cash Flow | 9.4 M |
Petros |
Petros Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 36.00 in Petros Pharmaceuticals on August 28, 2024 and sell it today you would lose (7.00) from holding Petros Pharmaceuticals or give up 19.44% of portfolio value over 90 days. Petros Pharmaceuticals is currently does not generate positive expected returns and assumes 6.263% risk (volatility on return distribution) over the 90 days horizon. In different words, 55% of stocks are less volatile than Petros, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Petros Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Petros Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Petros Pharmaceuticals, and traders can use it to determine the average amount a Petros Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.026
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PTPI |
Estimated Market Risk
| 6.26 actual daily | 55 55% of assets are less volatile |
Expected Return
| -0.16 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Petros Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Petros Pharmaceuticals by adding Petros Pharmaceuticals to a well-diversified portfolio.
Petros Pharmaceuticals Fundamentals Growth
Petros Stock prices reflect investors' perceptions of the future prospects and financial health of Petros Pharmaceuticals, and Petros Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Petros Stock performance.
| Return On Equity | -0.64 | ||||
| Return On Asset | -0.31 | ||||
| Profit Margin | (1.71) % | ||||
| Operating Margin | (1.60) % | ||||
| Current Valuation | 26.75 M | ||||
| Shares Outstanding | 10.01 M | ||||
| Price To Book | 0.87 X | ||||
| Price To Sales | 0.66 X | ||||
| Revenue | 5.82 M | ||||
| Gross Profit | 6.21 M | ||||
| EBITDA | (4.21 M) | ||||
| Net Income | (8.16 M) | ||||
| Cash And Equivalents | 13.3 M | ||||
| Cash Per Share | 0.64 X | ||||
| Total Debt | 8.28 M | ||||
| Debt To Equity | 0.31 % | ||||
| Current Ratio | 3.10 X | ||||
| Book Value Per Share | 4.04 X | ||||
| Cash Flow From Operations | (7.63 M) | ||||
| Earnings Per Share | (3.80) X | ||||
| Market Capitalization | 2.7 M | ||||
| Total Asset | 33.8 M | ||||
| Retained Earnings | (98.89 M) | ||||
| Working Capital | 9.62 M | ||||
About Petros Pharmaceuticals Performance
By evaluating Petros Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Petros Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Petros Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Petros Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 360.34 | 378.36 | |
| Return On Tangible Assets | (0.33) | (0.35) | |
| Return On Capital Employed | (0.59) | (0.62) | |
| Return On Assets | (0.24) | (0.25) | |
| Return On Equity | (0.65) | (0.62) |
Things to note about Petros Pharmaceuticals performance evaluation
Checking the ongoing alerts about Petros Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Petros Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Petros Pharmaceuticals generated a negative expected return over the last 90 days | |
| Petros Pharmaceuticals has high historical volatility and very poor performance | |
| Petros Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Petros Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 5.82 M. Net Loss for the year was (8.16 M) with profit before overhead, payroll, taxes, and interest of 6.21 M. | |
| Petros Pharmaceuticals currently holds about 13.3 M in cash with (7.63 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.64, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from MacroaxisInsider: Acquisition by Gesek Andrew of tradable shares of Petros Pharmaceuticals at 3.99 subject to Rule 16b-3 |
- Analyzing Petros Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Petros Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Petros Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Petros Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Petros Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Petros Pharmaceuticals' stock. These opinions can provide insight into Petros Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Petros Stock analysis
When running Petros Pharmaceuticals' price analysis, check to measure Petros Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Petros Pharmaceuticals is operating at the current time. Most of Petros Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Petros Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Petros Pharmaceuticals' price. Additionally, you may evaluate how the addition of Petros Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |